COMy 2022 | Advances in AL amyloidosis
In this video, Giampaolo Merlini, MD, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, discusses some key points from his presentation at COMy 2022, which focused on advances in AL amyloidosis, including early diagnosis, novel agents, and response criteria. Prof. Merlini first discusses the importance of early diagnosis in amyloidosis and how this can improve outcomes for patients. Prof. Merlini also comments on advances in this area, including the use of artificial intelligence and machine learning for early diagnosis and detection of amyloid light chains. To conclude, Prof. Merlini highlights the importance of achieving a deep and rapid complete response, the benefits of using measurable residual disease (MRD) in some patients, and the importance of using criteria to grade renal and cardiac response. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Advisory board: Pfizer and Janssen
